In regeneration studies, the FXR agonist OCA exhibited 100-fold greater efficacy than endogenous ligands in treating NASH-related fibrosis, with robust clinical benefits and safety evidence for improving NASH fibrosis. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.